Immunotherapy of cancer with 4-1BB

Molecular Cancer Therapeutics

Volumn 11, Issue 5, 2012, Pages 1062-1070

  Vinay, Dass S ^a   Kwon, Byoung S ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BMS 469492; BMS 666513; CD137 ANTIGEN; CD137 LIGAND; CYTOKINE; DENDRITIC CELL VACCINE; FLUOROURACIL; FUSION PROTEIN HIG HU4 1BB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4 1BB; RECOMBINANT INTERLEUKIN 12; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SURVIVAL; COLON CARCINOMA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIARRHEA; FATIGUE; FEVER; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PRURITUS; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR REGRESSION;

4-1BB LIGAND; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; MICE; MICE, KNOCKOUT; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84862739640     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0677     Document Type: Review

References (76)

1. Vinay DS, Cha K, Kwon BS. Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med (Berl) 2006;84:726-36. (Pubitemid 44328064)
2. Kwon BS, Weissman SM. cDNA sequences of two inducible T-cell genes. Proc Natl Acad Sci U S A 1989;86:1963-7. (Pubitemid 19087048)
3. Vinay DS, Kwon BS. Role of 4-1BB in immune responses. Semin Immunol 1998;10:481-9. (Pubitemid 28564377)
4. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-20. (Pubitemid 37328664)
5. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68. (Pubitemid 40563164)
6. Vinay DS, Kwon BS. 4-1BB signaling beyond T cells. Cell Mol Immunol 2011;8:281-4.
7. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997;186:47-55. (Pubitemid 27304846)
8. Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, et al. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10:1088-94. (Pubitemid 39424870)
9. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999;162:5037-40. (Pubitemid 29307099)
10. Sun Y, Lin X, Chen HM, Wu Q, Subudhi SK, Chen L, et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002;168:1457-65. (Pubitemid 34094519)
11. Foell J, Strahotin S, O'Neil SP, McCausland MM, Suwyn C, Haber M, et al. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice. J Clin Invest 2003;111:1505-18. (Pubitemid 38063283)
12. Sun Y, Chen HM, Subudhi SK, Chen J, Koka R, Chen L, et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2003;8:1405-13.
13. Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J Exp Med 1999;190:1535-40.
14. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007;178:4194-213. (Pubitemid 46492370)
15. Vinay DS, Kwon BS. TNF superfamily: costimulation and clinical applications. Cell Biol Int 2009;33:453-65.
16. Hong HJ, Lee JW, Park SS, Kang YJ, Chang SY, Kim KM, et al. A humanized anti-4-1BB monoclonal antibody suppresses antigeninduced humoral immune response in nonhuman primates. J Immunother 2000;23:613-21.
17. Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. Peptide-specific CD8 T regulatory cells use IFN-g to elaborate TGF-b-based suppression. J Immunol 2005;174:7625-32. (Pubitemid 40806267)
18. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5. (Pubitemid 27264981)
19. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998;190:167-72. (Pubitemid 29011104)
20. Sabel MS, Conway TF, Chen FA, Bankert RB. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice. J Immunother 2000;23:362-8. (Pubitemid 30327371)
21. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, et al. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 2001;61:2031-7. (Pubitemid 32692024)
22. Wilcox RA, Flies DB, Zhu G, Johnson AJ, Tamada K, Chapoval AI, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9. (Pubitemid 34204844)
23. May KF Jr, Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002; 62:3459-65. (Pubitemid 34651393)
24. Miller RE, Jones J, Le T, Whitmore J, Boiani N, Gliniak B, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002;169:1792-800. (Pubitemid 34857639)
25. Ju SA, Cheon SH, Park SM, TamNQ, Kim YM, AnWG,et al. Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int J Cancer 2008; 122:2784-90.
26. Palaźon A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011;71:801-11.
27. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117:1466-76. (Pubitemid 46871329)
28. Hernandez-Chacon JA, Li Y, Wu RC, Bernatchez C, Wang Y, Weber JS, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother 2011;34:236-50.
29. Zhu BQ, Ju SW, Shu YQ. CD137 enhances cytotoxicity of CD3(+)CD56 (+) cells and their capacities to induce CD4(+) Th1 responses. Biomed Pharmacother 2009;63:509-16.
30. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153:1687-96. (Pubitemid 24251113)
31. Verneris MR, Arshi A, Edinger M, Kornacker M, Natkunam Y, Karami M, et al. Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res 2005;11:4561-70. (Pubitemid 40825647)
32. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
33. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
34. Tammana S, Huang X, Wong M, Milone MC, Ma L, Levine BL, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther 2010;21:75-86.
35. Song D, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. Improved survival provided by CD137 costimulatory signaling to folate receptor-redirected T cells results in tumor localization and eradication. Cancer Res 2011;171:4617-27.
36. Ye Z, Hellstr̈om I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstr̈omKE. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 2002;8:343-8.
37. Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SHNK. NK and CD8+ T cellmediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004;109:499-506. (Pubitemid 38339639)
38. Tirapu I, Arina A, Mazzolini G, Duarte M, Alfaro C, Feijoo E, et al. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer 2004;110:51-60. (Pubitemid 38507203)
39. Ito F, Li Q, Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, et al. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res 2004;64:8411-9. (Pubitemid 39491781)
40. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006;66:7276-84. (Pubitemid 44197709)
41. Chen SH, Pham-Nguyen KB, Martinet O, Huang Y, Yang W, Thung SN, et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol Ther 2000;2:39-46.
42. Shi W, Siemann DW. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res 2006; 26[5A]:3445-53. (Pubitemid 44701521)
43. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
44. Wu HC, Li PC. Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J Cancer Mol 2008;4: 17-22.
45. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res 2007;67:7875-84. (Pubitemid 47281383)
46. Li B, Lin J, Vanroey M, Jure-Kunkel M, Jooss K. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin Immunol 2007;125:76-87. (Pubitemid 47374542)
47. Choi BK, Kim YH, Kang WJ, Lee SK, Kim KH, Shin SM, et al. Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res 2007;67:8891-9. (Pubitemid 47437466)
48. Geiger JD, Wagner PD, Cameron MJ, Shu S, Chang AE. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J Immunother Emphasis Tumor Immunol 1993;13:153-65. (Pubitemid 23093222)
49. Kim YH, Choi BK, Oh HS, Kang WJ, Mittler RS, Kwon BS. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther 2009;8:469-78.
50. Martinet O, Divino CM, Zang Y, Gan Y, Mandeli J, Thung S, et al. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther 2002;9:786-92. (Pubitemid 34679306)
51. Yoshida H, Katayose Y, Unno M, Suzuki M, Kodama H, Takemura S, et al. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol Immunother 2003;52:97-106. (Pubitemid 36337617)
52. Yan X, Johnson BD, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 2004;112:105-16. (Pubitemid 38609828)
53. Houtenbos I, Westers TM, Dijkhuis A, de Gruijl TD, Ossenkoppele GJ, van de Loosdrecht AA. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clin Cancer Res 2007;13:307-15. (Pubitemid 46121884)
54. Zhang N, Sadun RE, Arias RS, Flanagan ML, Sachsman SM, Nien YC, et al. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin Cancer Res 2007;13:2758-67. (Pubitemid 46788045)
55. McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 2008;118:376-86.
56. Guo H, Jiang W, Liu W, Gao Y, Yang M, Zhou Y, et al. Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Cell Immunol 2008;251:102-8.
57. Li Q, Ai J, Song Z, Liu J, Shan B. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo. Cell Mol Immunol 2008;5:379-84.
58. Baessler T, Charton JE, Schmiedel BJ, Grünebach F, Krusch M, Wacker A, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 2010;115:3058-69.
59. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010;116:1726-33.
60. Gullo C, Koh LK, Pang WL, Ho KT, Tan SH, Schwarz H. Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS ONE 2010;5:e10845.
61. Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, et al. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes. Clin Immunol 2010;137:221-33.
62. Ju SA, Lee SC, Kwon TH, Heo SK, Park SM, PaekHN, et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005;83:344-51.
63. Sun Y, Blink SE, Chen JH, Fu YX. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling. J Immunol 2005;175:884-90. (Pubitemid 41094971)
64. Middendorp S, Xiao Y, Song JY, Peperzak V, Krijger PH, Jacobs H, et al. Mice deficient for CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 2009;114:2280-9.
65. Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol 2004;173:4218-29. (Pubitemid 39280788)
66. Broll K, Richter G, Pauly S, Hofstaedter F, Schwarz H. CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol 2001;115:543-9. (Pubitemid 32275946)
67. Wan YL, Zheng SS, Zhao ZC, Li MW, Jia CK, Zhang H. Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J Gastroenterol 2004;10:195-9. (Pubitemid 38195260)
68. Palma C, Binaschi M, Bigioni M, MaggiCA, Goso C. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival. Int J Cancer 2004;108:390-8. (Pubitemid 37549604)
69. Salih HR, Schmetzer HM, Burke C, Starling GC, Dunn R, Pelka- Fleischer R, et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 2001;167:4059-66. (Pubitemid 32910853)
70. Dimberg J, Hugander A,Wågsäter D. Expression of CD137 and CD137 ligand in colorectal cancer patients. Oncol Rep 2006;15:1197-200.
71. Hentschel N, Krusch M, Kiener PA, Kolb HJ, Salih HR, Schmetzer HM. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. Eur J Haematol 2006;77:91-101.
72. Wang Q, Zhang P, Zhang Q, Wang X, Li J, Ma C, et al. Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J 2008;49:192-200. (Pubitemid 351669459)
73. Shoa Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor family, regulated immune responses via reverse signal transduction. J Leukobiol 2010;89:21-9.
74. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 26: 2008 (May 20 suppl; abstr 3007).
75. Meseck M, Huang T, Ma G, Wang G, Chen SH, Woo SLC. A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother 2011;34:175-82.
76. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.